In the EMBRACE phase 2 study, researchers reported efficacy for olaparib in metastatic triple-negative breast cancer (TNBC) and platinum-sensitive relapsed ovarian cancer with homologous recombination (HR) deficiency, even when germline BRCA1/2 mutations are absent. The results challenge a common assumption that PARP benefit is limited to BRCA-mutant subsets. The trial’s focus on HR deficiency without germline BRCA mutations expands the biomarker frame for patient selection in PARP inhibitor strategies, potentially increasing the treatable population among hard-to-manage metastatic patients. While details on endpoints and magnitude are not included in the provided excerpt, the reporting language indicates clinically meaningful support for olaparib in this genetically defined context. For biotech decision-makers, the data underscore continued momentum to refine companion and companion-like diagnostics around HR deficiency—potentially shifting recruitment and market expectations for PARP inhibitor programs beyond traditional BRCA labeling.